Serial Number 79307816
Registration 6749208
700

Registration Progress

Application Filed
Jan 12, 2021
Under Examination
Approved for Publication
Mar 22, 2022
Published for Opposition
Mar 22, 2022
Registered
Jun 7, 2022

Trademark Image

Basic Information

Serial Number
79307816
Registration Number
6749208
Filing Date
January 12, 2021
Registration Date
June 7, 2022
Published for Opposition
March 22, 2022
Drawing Code
2

Status Summary

Current Status
Active
Status Code
700
Status Date
Jun 7, 2022
Registration
Registered
Classes
005

Rights Holder

The Binding Site Group Limited

99
Address
8 Calthorpe Road
Edgbaston, Birmingham
West Midlands, B15 1QT
GB

Ownership History

The Binding Site Group Limited

Original Applicant
99
West Midlands GB

The Binding Site Group Limited

Owner at Publication
99
West Midlands GB

The Binding Site Group Limited

Original Registrant
99
West Midlands, B15 1QT GB

Legal Representation

Attorney
Melissa A. Vallone

USPTO Deadlines

Next Deadline
1060 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2022-06-07)
Due Date
June 07, 2028
Grace Period Ends
December 07, 2028
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

32 events
Date Code Type Description
Apr 21, 2024 NREP P NEW REPRESENTATIVE AT IB RECEIVED
May 30, 2023 NURC C NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
Apr 24, 2023 APRE A CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Apr 24, 2023 COC. O CORRECTION UNDER SECTION 7 - PROCESSED
Apr 21, 2023 APRE A CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Oct 17, 2022 FINO P FINAL DECISION TRANSACTION PROCESSED BY IB
Sep 22, 2022 FICS P FINAL DISPOSITION NOTICE SENT TO IB
Sep 22, 2022 FIMP P FINAL DISPOSITION PROCESSED
Sep 7, 2022 FICR P FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jul 1, 2022 ES7R I TEAS SECTION 7 REQUEST RECEIVED
Jun 7, 2022 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jun 7, 2022 R.PR A REGISTERED-PRINCIPAL REGISTER
Mar 22, 2022 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 22, 2022 PUBO A PUBLISHED FOR OPPOSITION
Mar 21, 2022 GPNX P NOTIFICATION PROCESSED BY IB
Mar 2, 2022 OPNS P NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 2, 2022 OP2R P NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Mar 2, 2022 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 14, 2022 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 21, 2022 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 20, 2022 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 20, 2022 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 2, 2021 NREP P NEW REPRESENTATIVE AT IB RECEIVED
Sep 5, 2021 RFNT P REFUSAL PROCESSED BY IB
Aug 16, 2021 RFCS P NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 16, 2021 RFRR P REFUSAL PROCESSED BY MPU
Aug 3, 2021 RFCR E NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 2, 2021 CNRT R NON-FINAL ACTION WRITTEN
Jul 22, 2021 DOCK D ASSIGNED TO EXAMINER
Apr 13, 2021 MAFR O APPLICATION FILING RECEIPT MAILED
Apr 7, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 1, 2021 REPR M SN ASSIGNED FOR SECT 66A APPL FROM IB

Detailed Classifications

Class 005
Diagnostic kits consisting primarily of antibodies, buffers and reagents for use in measuring proteins, antibodies, antigens and other substances in the blood, other bodily fluids and body tissues for the diagnosis of disease and other conditions in humans and animals in the fields of cancer, immunology and haemotology; immunological test kits consisting primarily of diagnostic preparations for use in measuring proteins, antibodies, antigens and other substances in the blood, other bodily fluids and body tissues for the diagnosis of disease and other conditions in humans and animals in the fields of cancer, immunology and haemotology; reagents for use in medical diagnosis; diagnostic and biological reagents for medical use; medical diagnostic assays, namely antibodies, nephelometric assays, turbidimetric assays, chemistry assays and enzyme assays for testing of bodily fluids; calibrating solutions for medical diagnostic assays for testing of bodily fluids; diluents for medical diagnostic assays for testing of bodily fluids; control samples for medical diagnostic assays for testing of bodily fluids; none of the aforesaid products to be used in relation to dialysis and/or fluid therapy

Additional Information

Design Mark
The mark consists of three oblong ovals connected in the center and forming the shape of a triangle within a triangle.
Other
In the statement, line 3, "QT" should be inserted.

Classification

International Classes
005

USPTO Documents

Click to view cached USPTO documents for this trademark

Only administrators can request new documents from USPTO